Bridging the Gaps in Autoimmune Research Discovery and Mindpeak Partner to Advance AI Biomarker Testing for Clinical Trials Take Advantage of High-Quality Legacy Biospecimens How to Discover Biomarkers with Proteogenomics Annual Spring Sale is Here! Click Here to Learn More
Bridging the Gaps in Autoimmune Research Discovery and Mindpeak Partner to Advance AI Biomarker Testing for Clinical Trials Take Advantage of High-Quality Legacy Biospecimens How to Discover Biomarkers with Proteogenomics Annual Spring Sale is Here! Click Here to Learn More
DISCOVERY BIOSTORE™
CONTACT US

Biospecimens & Biomarker Testing for Precision Oncology Programs

Your breakthrough cancer research begins with diverse and well-characterized biospecimens. Discovery Life Sciences has an extensive inventory of human cancer samples, CLIA/CAP-certified service laboratories, and a team of experts dedicated to your cause. 
TALK TO A BIOMARKER EXPERT

Better Cancer Biospecimens for Better Patient Outcomes

The cure is out there, and it starts with you and the biospecimens powering your research. Explore our diverse range of highly characterized human cancer biospecimens for your precision oncology program.

FFPE

Cell and gene therapy is transforming what’s possible with cancer research and treatment – but only with reliable, high-quality cellular starting materials and appropriate process analytics. Get both from Discovery and AllCells. 

DTC

Diseased and benign dissociated tissue and tumor cells (DTCs).

Biofluids

Blood-based biospecimens, including fresh whole blood, double-spun plasma, serum, buffy coat, cord blood and bone marrow.

Matched Sets

Matched donor biospecimen sets across various biospecimen formats.

Biofluids (Other)

Non-blood biofluid biospecimens, including urine, saliva, aspirate, cerebrospinal fluid (CSF), oral swab, bronchoalveolar lavage (BAL), nasal fluid, synovial fluid, sputum and other biofluid biospecimens.

BMMCs

Diseased and healthy bone marrow mononuclear cells (BMMCs) with flow cytometric immunophenotypic data available.

Immune Cell Isolations

Isolated immune cells from healthy donors, all tested for viruses like HIV, HBV, HCV, and CMV.

Normal (Controls)

Highly characterized human cellular starting materials with 2,800+ recallable donors – paired with world-class genomics and flow cytometry labs.

Revolutionize Cancer Research with Cell & Gene Therapy

Cell and gene therapy is transforming what’s possible with cancer research and treatment – but only with reliable, high-quality cellular starting materials and appropriate process analytics. Get both from Discovery and AllCells. 
ACCELERATE YOUR CGT PROGRAM

Further Characterize Cancer Biospecimens (Yours or Ours)

We provide deeper multiomic biomarker analyses to further characterize biospecimens from our inventory or your studies.
GENOMIC BIOMARKERS
  • HudsonAlpha Discovery
  • Whole genome sequencing
  • Whole exome sequencing
  • Targeted panels
  • Long-read sequencing
  • RNASeq
  • Single cell sequencing
PATHOLOGY-GUIDED TISSUE BIOMARKERS
  • Multiplexed and singleplex IHC
  • In-situ hybridization
  • RNAScope
    Digital pathology and image analysis
  • PCR
  • Immunoflourescence
    Colorimetric
CELL-BASED BIOMARKERS
  • HudsonAlpha Discovery
  • Whole genome sequencing
  • Whole exome sequencing
  • Targeted panels
  • Long-read sequencing
  • RNASeq
  • Single cell sequencing

Oncology Reading & Resources for You

An Assay Platform to Evaluate Cytokine Secretion & T Cell Activation

eBooks

AACR 2026 – Bone marrow from acute myeloid leukemia (AML) and multiple myeloma (MM) patients can be used to evaluate target expression and on-target efficacy for novel antibody drug conjugates (ADCs)

AACR 2026 – Integrated proteogenomics of primary tumoroid models for precision

AACR 2026 – Development and Validation of an Optimized, Bead-Based Dual Nucleic Acid Extraction Method for High-Yield Genomic Profiling of Scarce FFPE Tumor Specimens

AACR 2026 – Establishing Quantitative Image Analysis Driven Multiplex Immunofluorescence Panels for Retrospective Clinical Research

AACR 2026 – Evaluation of tumor-infiltrating T cells across solid tumor indications

AACR 2026 – Exploring the molecular landscape of ovarian cancer through immunohistochemistry multi-marker prevalence screening

Tell Us About Your Oncology Project’s Needs

[wpforms id="4825"]

Popular Keywords

Categories,Pages

No Record Found

View All Results
Quick Links

Markets We Serve

Resources

Privacy Settings